Successful early-stage innovation deals: Pharma and biotech partners divulge specifics

Edition

Successful early-stage innovation deals: Pharma and biotech partners divulge specifics

What are pharma companies awaiting from the start-ups they would like to interact with?
Learn from success stories of pharma-biotech collaborations through successful deals they made. What were the hurdles to these deals? What are the keys to carry a good partnership? What are the factors of success and how to handle them? When is it the best time to go meet with pharma for a biotech start-up?

Learn from figures and statistics: how many people get a deal at the end? How to picture an innovation in the best possible way to make a deal? How interactions between early-stage projects and pharma help anticipate pitfalls at the very early development stages? How innovative products have proven to come out of these deals?

This session advocates that a problem shared is a problem solved.

Gerald Law

Chief Executive
United Kingdom
Innovation DB

Loic Lhuillier

Chief Operating Officer
United Kingdom
Exonate Ltd

Jochen Maas

General Manager R&D Germany
Germany
Sanofi

Shane Maloney

Global Head of Transactions
France
Servier

Luc Boblet

Founder and CEO
France
Egle Therapeutics

Phil L’Huillier

Head of Business Development, Europe
United Kingdom
MSD
  • No products in the cart.